Which has higher valuation & earnings, MASI or OMCL?

Omnicell has lower revenue, but higher earnings than Masimo. Masimo is trading at a lower price-to-earnings ratio than Omnicell, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Masimo $1.56B 6.05 -$151.50M -$10.54 N/A Omnicell $1.23B 1.43 $2.05M $0.44 87.50

Is MASI or OMCL more profitable?

Masimo has a net margin of 4.90% compared to Omnicell's net margin of 1.67%. Masimo's return on equity of 31.33% beat Omnicell's return on equity. Company Net Margins Return on Equity Return on Assets Masimo 4.90% 31.33% 13.93% Omnicell 1.67% 4.00% 2.46%

Do analysts recommend MDRX or OMCL?

Omnicell has a consensus price target of $59.86, indicating a potential upside of 55.47%. Given Omnicell's stronger consensus rating and higher possible upside, analysts plainly believe Omnicell is more favorable than Veradigm. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Veradigm 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Omnicell 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.00

Which has preferable valuation & earnings, MDRX or OMCL?

Omnicell has lower revenue, but higher earnings than Veradigm. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Veradigm $1.53B 0.38 N/A N/A N/A Omnicell $1.23B 1.43 $2.05M $0.44 87.50

Is MDRX or OMCL more profitable?

Omnicell has a net margin of 1.67% compared to Veradigm's net margin of 0.00%. Omnicell's return on equity of 4.00% beat Veradigm's return on equity. Company Net Margins Return on Equity Return on Assets Veradigm N/A N/A N/A Omnicell 1.67% 4.00% 2.46%

Omnicell (OMCL) Competitors

$38.50 -1.40 (-3.51%)

Closing price 06/17/2026 04:00 PM Eastern

Extended Trading

$38.80 +0.30 (+0.78%)

As of 09:19 AM Eastern

Compare

OMCL vs. MASI, AMN, WST, HSTM, and MDRX

Should you buy Omnicell stock or one of its competitors? MarketBeat compares Omnicell with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Omnicell include Masimo (MASI), AMN Healthcare Services (AMN), West Pharmaceutical Services (WST), HealthStream (HSTM), and Veradigm (MDRX).

How does Omnicell compare to Masimo?

Masimo (NASDAQ:MASI) and Omnicell (NASDAQ:OMCL) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, media sentiment, institutional ownership, risk, valuation, earnings and dividends.

Masimo has a net margin of 4.90% compared to Omnicell's net margin of 1.67%. Masimo's return on equity of 31.33% beat Omnicell's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Masimo	4.90%	31.33%	13.93%
Omnicell	1.67%	4.00%	2.46%

Masimo has a beta of 1.11, meaning that its share price is 11% more volatile than the broader market. Comparatively, Omnicell has a beta of 0.97, meaning that its share price is 3% less volatile than the broader market.

86.0% of Masimo shares are held by institutional investors. Comparatively, 97.7% of Omnicell shares are held by institutional investors. 9.7% of Masimo shares are held by insiders. Comparatively, 2.9% of Omnicell shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Masimo had 1 more articles in the media than Omnicell. MarketBeat recorded 1 mentions for Masimo and 0 mentions for Omnicell. Omnicell's average media sentiment score of 0.67 beat Masimo's score of 0.22 indicating that Omnicell is being referred to more favorably in the news media.

Company	Overall Sentiment
Masimo	Neutral
Omnicell	Positive

Masimo presently has a consensus target price of $180.40, suggesting a potential upside of 0.25%. Omnicell has a consensus target price of $59.86, suggesting a potential upside of 55.47%. Given Omnicell's stronger consensus rating and higher probable upside, analysts clearly believe Omnicell is more favorable than Masimo.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Masimo	0 Sell rating(s)	9 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Omnicell	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	3.00

Omnicell has lower revenue, but higher earnings than Masimo. Masimo is trading at a lower price-to-earnings ratio than Omnicell, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Masimo	$1.56B	6.05	-$151.50M	-$10.54	N/A
Omnicell	$1.23B	1.43	$2.05M	$0.44	87.50

Summary

Omnicell beats Masimo on 9 of the 17 factors compared between the two stocks.

How does Omnicell compare to AMN Healthcare Services?

AMN Healthcare Services (NYSE:AMN) and Omnicell (NASDAQ:OMCL) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, media sentiment, risk, valuation, dividends and earnings.

Omnicell has lower revenue, but higher earnings than AMN Healthcare Services. AMN Healthcare Services is trading at a lower price-to-earnings ratio than Omnicell, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AMN Healthcare Services	$2.73B	0.46	-$95.70M	-$0.87	N/A
Omnicell	$1.23B	1.43	$2.05M	$0.44	87.50

In the previous week, AMN Healthcare Services had 5 more articles in the media than Omnicell. MarketBeat recorded 5 mentions for AMN Healthcare Services and 0 mentions for Omnicell. Omnicell's average media sentiment score of 0.67 beat AMN Healthcare Services' score of 0.35 indicating that Omnicell is being referred to more favorably in the news media.

Company	Overall Sentiment
AMN Healthcare Services	Neutral
Omnicell	Positive

99.2% of AMN Healthcare Services shares are held by institutional investors. Comparatively, 97.7% of Omnicell shares are held by institutional investors. 1.1% of AMN Healthcare Services shares are held by company insiders. Comparatively, 2.9% of Omnicell shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Omnicell has a net margin of 1.67% compared to AMN Healthcare Services' net margin of -0.95%. AMN Healthcare Services' return on equity of 18.01% beat Omnicell's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AMN Healthcare Services	-0.95%	18.01%	5.19%
Omnicell	1.67%	4.00%	2.46%

AMN Healthcare Services currently has a consensus price target of $25.29, suggesting a potential downside of 22.10%. Omnicell has a consensus price target of $59.86, suggesting a potential upside of 55.47%. Given Omnicell's stronger consensus rating and higher probable upside, analysts clearly believe Omnicell is more favorable than AMN Healthcare Services.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AMN Healthcare Services	2 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.22
Omnicell	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	3.00

AMN Healthcare Services has a beta of 0.44, suggesting that its stock price is 56% less volatile than the broader market. Comparatively, Omnicell has a beta of 0.97, suggesting that its stock price is 3% less volatile than the broader market.

Summary

Omnicell beats AMN Healthcare Services on 12 of the 17 factors compared between the two stocks.

How does Omnicell compare to West Pharmaceutical Services?

West Pharmaceutical Services (NYSE:WST) and Omnicell (NASDAQ:OMCL) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, dividends, risk, analyst recommendations, profitability, valuation and earnings.

West Pharmaceutical Services has a net margin of 16.85% compared to Omnicell's net margin of 1.67%. West Pharmaceutical Services' return on equity of 19.03% beat Omnicell's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
West Pharmaceutical Services	16.85%	19.03%	14.06%
Omnicell	1.67%	4.00%	2.46%

West Pharmaceutical Services presently has a consensus price target of $340.09, indicating a potential upside of 5.25%. Omnicell has a consensus price target of $59.86, indicating a potential upside of 55.47%. Given Omnicell's higher probable upside, analysts plainly believe Omnicell is more favorable than West Pharmaceutical Services.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
West Pharmaceutical Services	0 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00
Omnicell	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	3.00

In the previous week, West Pharmaceutical Services had 12 more articles in the media than Omnicell. MarketBeat recorded 12 mentions for West Pharmaceutical Services and 0 mentions for Omnicell. West Pharmaceutical Services' average media sentiment score of 1.25 beat Omnicell's score of 0.67 indicating that West Pharmaceutical Services is being referred to more favorably in the media.

Company	Overall Sentiment
West Pharmaceutical Services	Positive
Omnicell	Positive

93.9% of West Pharmaceutical Services shares are owned by institutional investors. Comparatively, 97.7% of Omnicell shares are owned by institutional investors. 0.6% of West Pharmaceutical Services shares are owned by company insiders. Comparatively, 2.9% of Omnicell shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

West Pharmaceutical Services has a beta of 1.18, suggesting that its stock price is 18% more volatile than the broader market. Comparatively, Omnicell has a beta of 0.97, suggesting that its stock price is 3% less volatile than the broader market.

West Pharmaceutical Services has higher revenue and earnings than Omnicell. West Pharmaceutical Services is trading at a lower price-to-earnings ratio than Omnicell, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
West Pharmaceutical Services	$3.07B	7.43	$493.70M	$7.48	43.20
Omnicell	$1.23B	1.43	$2.05M	$0.44	87.50

Summary

West Pharmaceutical Services beats Omnicell on 12 of the 16 factors compared between the two stocks.

How does Omnicell compare to HealthStream?

Omnicell (NASDAQ:OMCL) and HealthStream (NASDAQ:HSTM) are both small-cap health care technology companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, institutional ownership, media sentiment, valuation, dividends, earnings and profitability.

97.7% of Omnicell shares are held by institutional investors. Comparatively, 69.6% of HealthStream shares are held by institutional investors. 2.9% of Omnicell shares are held by insiders. Comparatively, 20.4% of HealthStream shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Omnicell presently has a consensus price target of $59.86, suggesting a potential upside of 55.47%. HealthStream has a consensus price target of $24.00, suggesting a potential downside of 7.69%. Given Omnicell's stronger consensus rating and higher possible upside, analysts clearly believe Omnicell is more favorable than HealthStream.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Omnicell	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	3.00
HealthStream	0 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

HealthStream has lower revenue, but higher earnings than Omnicell. HealthStream is trading at a lower price-to-earnings ratio than Omnicell, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Omnicell	$1.23B	1.43	$2.05M	$0.44	87.50
HealthStream	$304.06M	2.50	$18.34M	$0.67	38.81

HealthStream has a net margin of 6.39% compared to Omnicell's net margin of 1.67%. HealthStream's return on equity of 6.47% beat Omnicell's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Omnicell	1.67%	4.00%	2.46%
HealthStream	6.39%	6.47%	4.44%

Omnicell has a beta of 0.97, meaning that its stock price is 3% less volatile than the broader market. Comparatively, HealthStream has a beta of 0.47, meaning that its stock price is 53% less volatile than the broader market.

In the previous week, HealthStream had 2 more articles in the media than Omnicell. MarketBeat recorded 2 mentions for HealthStream and 0 mentions for Omnicell. Omnicell's average media sentiment score of 0.67 beat HealthStream's score of 0.34 indicating that Omnicell is being referred to more favorably in the media.

Company	Overall Sentiment
Omnicell	Positive
HealthStream	Neutral

Summary

Omnicell beats HealthStream on 9 of the 17 factors compared between the two stocks.

How does Omnicell compare to Veradigm?

Veradigm (NASDAQ:MDRX) and Omnicell (NASDAQ:OMCL) are both small-cap health care technology companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, dividends, analyst recommendations, risk, media sentiment and valuation.

Veradigm has a beta of 0.55, suggesting that its stock price is 45% less volatile than the broader market. Comparatively, Omnicell has a beta of 0.97, suggesting that its stock price is 3% less volatile than the broader market.

Omnicell has a net margin of 1.67% compared to Veradigm's net margin of 0.00%. Omnicell's return on equity of 4.00% beat Veradigm's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Veradigm	N/A	N/A	N/A
Omnicell	1.67%	4.00%	2.46%

Omnicell has a consensus price target of $59.86, indicating a potential upside of 55.47%. Given Omnicell's stronger consensus rating and higher possible upside, analysts plainly believe Omnicell is more favorable than Veradigm.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Veradigm	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Omnicell	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	3.00

Omnicell has lower revenue, but higher earnings than Veradigm.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Veradigm	$1.53B	0.38	N/A	N/A	N/A
Omnicell	$1.23B	1.43	$2.05M	$0.44	87.50

In the previous week, Omnicell's average media sentiment score of 0.67 beat Veradigm's score of 0.00 indicating that Omnicell is being referred to more favorably in the news media.

Company	Overall Sentiment
Veradigm	Neutral
Omnicell	Positive

97.7% of Omnicell shares are held by institutional investors. 2.3% of Veradigm shares are held by company insiders. Comparatively, 2.9% of Omnicell shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Omnicell beats Veradigm on 13 of the 14 factors compared between the two stocks.

Get Omnicell News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OMCL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

OMCL vs. The Competition

Export

Metric	Omnicell	MEDICAL INFO SYS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.75B	$1.56B	$6.51B	$12.22B
Dividend Yield	N/A	N/A	2.67%	5.70%
P/E Ratio	87.50	72.00	24.58	24.08
Price / Sales	1.43	7.23	523.33	119.41
Price / Cash	14.43	23.49	43.94	55.48
Price / Book	1.40	4.85	10.61	6.61
Net Income	$2.05M	-$54.76M	$3.57B	$337.89M
7 Day Performance	1.80%	-0.44%	0.22%	-0.15%
1 Month Performance	-10.92%	0.98%	3.32%	3.78%
1 Year Performance	36.19%	-6.07%	27.42%	29.20%

Omnicell Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
OMCL Omnicell	3.5324 of 5 stars	$38.50 -3.5%	$59.86 +55.5%	+35.1%	$1.75B	$1.23B	87.50	3,580
MASI Masimo	1.4746 of 5 stars	$179.94 +0.6%	$180.40 +0.3%	N/A	$9.36B	$1.53B	N/A	2,200
AMN AMN Healthcare Services	1.5641 of 5 stars	$30.93 -2.4%	$25.29 -18.3%	+47.9%	$1.23B	$2.73B	N/A	2,664	Insider Trade
WST West Pharmaceutical Services	3.6509 of 5 stars	$319.98 +1.7%	$331.91 +3.7%	+48.1%	$22.22B	$3.07B	42.78	10,800	Positive News
HSTM HealthStream	2.7788 of 5 stars	$25.65 +1.6%	$24.00 -6.4%	-5.1%	$737.39M	$304.06M	38.28	1,160	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:OMCL) was last updated on 6/18/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Omnicell (OMCL) Competitors

OMCL vs. MASI, AMN, WST, HSTM, and MDRX

How does Omnicell compare to Masimo?

Summary

How does Omnicell compare to AMN Healthcare Services?

Summary

How does Omnicell compare to West Pharmaceutical Services?

Summary

How does Omnicell compare to HealthStream?

Summary

How does Omnicell compare to Veradigm?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OMCL vs. The Competition

Omnicell Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Omnicell (OMCL) Competitors

OMCL vs. MASI, AMN, WST, HSTM, and MDRX

How does Omnicell compare to Masimo?

Is MASI or OMCL more profitable?

Which has more volatility & risk, MASI or OMCL?

Do institutionals & insiders have more ownership in MASI or OMCL?

Does the media prefer MASI or OMCL?

Do analysts rate MASI or OMCL?

Which has higher valuation & earnings, MASI or OMCL?

Summary

How does Omnicell compare to AMN Healthcare Services?

Which has preferable valuation & earnings, AMN or OMCL?

Does the media refer more to AMN or OMCL?

Do insiders & institutionals hold more shares of AMN or OMCL?

Is AMN or OMCL more profitable?

Do analysts rate AMN or OMCL?

Which has more volatility & risk, AMN or OMCL?

Summary

How does Omnicell compare to West Pharmaceutical Services?

Is WST or OMCL more profitable?

Do analysts rate WST or OMCL?

Does the media refer more to WST or OMCL?

Do institutionals and insiders believe in WST or OMCL?

Which has more risk and volatility, WST or OMCL?

Which has preferable valuation and earnings, WST or OMCL?

Summary

How does Omnicell compare to HealthStream?

Do institutionals & insiders have more ownership in OMCL or HSTM?

Do analysts recommend OMCL or HSTM?

Which has preferable earnings and valuation, OMCL or HSTM?

Is OMCL or HSTM more profitable?

Which has more risk & volatility, OMCL or HSTM?

Does the media favor OMCL or HSTM?

Summary

How does Omnicell compare to Veradigm?

Which has more risk and volatility, MDRX or OMCL?

Is MDRX or OMCL more profitable?

Do analysts recommend MDRX or OMCL?

Which has preferable valuation & earnings, MDRX or OMCL?

Does the media prefer MDRX or OMCL?

Do insiders and institutionals hold more shares of MDRX or OMCL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OMCL vs. The Competition

Omnicell Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools